714
PHARMACOTHERAPY Volume 21, Number 6, 2001
32. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update:
51. den Heijer P, Veemeer F, Ambrosioni E, et al. Evaluation of a
weight-adjusted single-bolus plasminogen activator in
patients with myocardial infarction: a double-blind,
randomized angiographic trial of lanoteplase versus alteplase.
Circulation 1998;98:2117–25.
52. Morris D. Results from late-breaking clinical trial sessions at
ACCIS ’99 and ACC ’99. J Am Coll Cardiol 1999;34:1–8.
53. Ferguson JJ. Highlights of the 48th scientific sessions of the
American College of Cardiology. Circulation 1999;100:570–5.
54. Antman EM, Wilcox RG, Giugliano RP, et al. Long-term
comparison of lanoteplase and alteplase in ST elevation
myocardial infarction: 6 month follow-up in In-TIME-II trial
[abstr]. Circulation 1999;100(suppl I):I-498.
ACC/AHA guidelines for management of patients with acute
myocardial infarction: executive summary and
recommendations: a report from the American College of
Cardiology/American Heart Association task force on practice
guidelines (Committee on Management of Acute Myocardial
Infarction). Circulation 1999;100:1016–30.
33. Boersma E, Akkerhuis M, Simoons ML. Primary angioplasty
versus thrombolysis for acute myocardial infarction [letter]. N
Engl J Med 2000;342:890–1.
34. Anonymous. Update: enhanced prehospital response to acute
myocardial infarction. New Era of Reperfusion Physician
Edition 1999;3:1–8.
35. Cannon CP, Sayah AJ, Walls RM. Pre-hospital thrombolysis:
an idea whose time has come. Clin Cardiol 1999;22(suppl
IV):I-10–19.
36. Barron HV, Bowlby LJ, Breen T, et al. Use of reperfusion
therapy for acute myocardial infarction in the United States:
data from the national registry of myocardial infarction 2.
Circulation 1998;97:1150–6.
37. The INJECT Study Group. Randomised, double-blind
comparison to reteplase double-bolus administration with
streptokinase in acute myocardial infarction (INJECT): trial to
investigate equivalence. Lancet 1995;346:329–36.
38. Smalling RW, Bode C, Kalbfeisch J, et al. More rapid,
complete, and stable coronary thrombolysis with bolus
administration of reteplase compared with alteplase infusion
in acute myocardial infarction. RAPID investigators.
Circulation 1995;91:2725–32.
39. Bode C, Smalling RW, Berg G, et al. Randomized comparison
of coronary thrombolysis achieved with double-bolus
reteplase (recombinant plasminogen activator) and front-
loaded, accelerated alteplase (recombinant tissue plasminogen
activator) in acute myocardial infarction. The RAPID II
investigators. Circulation 1996;94:891–8.
40. The Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO III) Investigators. A comparison of
reteplase with alteplase for acute myocardial infarction. N
Engl J Med 1997;337:1118–23.
41. Stringer KA. TIMI grade flow, mortality, and the GUSTO-III
trial. Pharmacotherapy 1998;18:699–705.
42. Ware JH, Antman EM. Equivalence trials. N Engl J Med
1997;337:1159–60.
43. Throm CD. Thrombolytic therapy for myocardial infarction
[letter]. N Engl J Med 1998;338:545.
44. Seyedroudbari A, Kessler ER, Mooss AN, Wurdeman RL,
Bala M, Hilleman DE. Time to treatment and cost of
thrombolysis: a multicenter comparison of tPA and rPA. J
Thromb Thrombol 2000;9:303–8.
45. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue
plasminogen activator in acute myocardial infarction: results
of the thrombolysis in myocardial infarction (TIMI) 10A dose-
ranging trial. Circulation 1997;95:351–6.
46. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue
plasminogen activator compared with front-loaded alteplase
in acute myocardial infarction: results of the TIMI 10B trial.
Circulation 1998;98:2805–14.
47. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment
of single-bolus administration of TNK tissue-plasminogen
activator in acute myocardial infarction: The ASSENT-1 trial.
The ASSENT investigators. Am Heart J 1999;137:786–91.
48. Assessment of the Safety and Efficacy of a New
Thrombolytic (ASSENT-2) Investigators. Single-bolus
tenecteplase compared with front-loaded alteplase in acute
myocardial infarction: the ASSENT-2 double-blind
randomised trial. Lancet 1999;354:716–22.
49. Nagao K, Satou K, Watanabe I, et al. Angiographic study of
mutant tissue-type plasminogen activator versus urokinase for
acute myocardial infarction. Jpn Circ J 1998;62:111–14.
50. Ogata N, Ogawa H, Ogata Y, et al. Comparison of
thrombolytic therapies with mutant tPA (lanoteplase/
SUN9216) and recombinant tPA (alteplase) for acute
myocardial infarction. Jpn Circ J 1998;62:801–6.
55. Giugliano RP, Antman EM, McCabe CH, et al. InTIMI-2b:
omission of heparin bolus lowers rate of intracranial
hemorrhage with lanoteplase [abstr]. J Am Coll Cardiol
2000;35(suppl A):407A.
56. The CORAMI Study Group. Outcome of attempted rescue
coronary angioplasty after failed thrombolysis for acute
myocardial infarction. Cohort of rescue angioplasty in
myocardial infarction. Am J Cardiol 1994;74:172–4.
57. Smalling RW, Bode C, Kalbfleisich J, et al. More rapid,
complete, and stable coronary thrombolysis with bolus
administration of reteplase compared with alteplase infusion
in acute myocardial infarction. Circulation 1995;91:2725–32.
58. White HD, Van de Werf FJJ. Clinical cardiology: new
frontiers: thrombolysis for acute myocardial infarction.
Circulation 1998;97:1632–46.
59. Davies CH, Ormerod OJM. Failed coronary thrombolysis.
Lancet 1998;351:1191–6.
60. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD,
Powers ER. Thrombolytic therapy with tissue plasminogen
activator or streptokinase induces transient thrombin activity.
Blood 1988;72:616–20.
61. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked
platelet activation in vivo after intravenous streptokinase in
patients with acute myocardial infarction. Circulation
1988;77:142–50.
62. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of
reteplase and alteplase on platelet aggregation and major
receptor expression during the first 24 hours of acute
myocardial infarction treatment. GUSTO-III investigators.
Global use of strategies to open occluded coronary arteries. J
Am Coll Cardiol 1998;31:1466–73.
63. De Lemos JA, Antman EM, Giugliano RP, et al. ST-segment
resolution and infarct-related patency and flow after
thrombolytic therapy. Am J Cardiol 2000;85:299–304.
64. Schroder R, Dissman R, Bruggermann T, et al. Extent of
early ST segment elevation resolution: a simple but strong
predictor of outcome in patients with acute myocardial
infarction. J Am Coll Cardiol 1994;24:384–91.
65. Rogers WJ, Baim DS, Gore JM, et al. Comparison of
immediate invasive, delayed invasive, and conservative
strategies after tissue-type plasminogen activator: results of
the thrombolysis in myocardial infarction (TIMI) phase II-A
trial. Circulation 1990;81:1457–76.
66. Abbottsmith CW, Topol EJ, George BS, et al. Fate of patients
with acute myocardial infarction with patency of the infarct-
related vessel achieved with successful thrombolysis versus
rescue angioplasty. J Am Coll Cardiol 1990;16:770–8.
67. Baim DS, Braunwald E, Feit F, et al. The thrombolysis in
myocardial infarction (TIMI) trial phase II: additional
information and perspectives. J Am Coll Cardiol
1990;15:1188–92.
68. Belenkie I, Traboulsi M, Hall CA, et al. Rescue angioplasty
during myocardial infarction has a beneficial effect on
mortality: a tenable hypothesis. Can J Cardiol 1992;8:357–62.
69. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized
comparison of rescue angioplasty with conservative
management of patients with early failure of thrombolysis for
acute anterior myocardial infarction. Circulation
1994;90:2280–4.
70. Ellis SG, da Silva ER, Spaulding CM, Nobuyoshi M, Wiener